An accomplished entrepreneur in the life sciences industry, Brad Margus has co-founded and led several life sciences companies, most recently founding Cerevance, Inc., a new drug discovery company. Prior to Cerevance, Mr. Margus started Genome Bridge, a non-profit subsidiary of the Broad Institute of Harvard and M.I.T., to build a computational platform for sharing genomic and clinical data. Previously, as co-founder and CEO of Envoy Therapeutics, Mr. Margus raised $8 million from investors, discovered new compounds for brain diseases, and sold the company to a global pharmaceutical company for $140 million. Earlier, he was co-founder and served as CEO of Perlegen Sciences, a leader in analyzing genetic variation. Concurrent with his business career, for the last 20 years, Mr. Margus has worked as founder and volunteer President of the A-T Children’s Project, a non-profit that orchestrates research on a rare, brutal, genetic disease – ataxia telangiectasia or “A-T” – that two of his sons have. A-T causes neurodegeneration, cancer and immune system problems. Mr. Margus co-chairs the Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT) External Oversight Board at the National Institutes of Health. He also serves on the Steering Committee for the Global Alliance for Genomics & Health and on the Board of Global Genes.